The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and ...

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

Geographic atrophy is a leading cause of blindness. The new approval will help to fill an unmet need for patients. The first ever treatment for geographic atrophy (GA) was approved by the FDA.

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Expert Rev of Obstet Gynecol. 2013;8(5):457-465. While treatments for vulvovaginal atrophy have often focused on the vagina, it is critical to address care for the vulvar vestibule as well. The ...

H LUNDBECK A/S ((HLUYY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

Ocugen, Inc. has completed enrollment in the Phase 2 portion of its clinical trial for OCU410, a novel gene therapy aimed at treating geographic atrophy (GA) associated with dry age-related macular ...